Back to results
US 12,472,147 B2Granted
Intestinal alkaline phosphatase formulations
AssigneeTheriva Biologics, Inc.
InventorsAndrew Bristol, Ray Stapleton, Michael Kaleko, Christian Furlan Freguia, Steven Hubert, Cristina Freire, James Gubbins
Life of this patent
Estimating the term…
Abstract
The present invention provides for a formulation comprising an active alkaline phosphatase (AP)-based agent and an enteric agent, wherein the formulation is suitable for releasing a substantial amount of the active AP-based agent in the intestines.
Claims18
A pharmaceutical formulation in the form of a tablet comprising:
- 37-43% by weight alkaline phosphatase (AP)-based agent, wherein the AP-based agent comprises an amino acid sequence at least 95% identical to the amino acid sequences set forth in SEQ ID NOs:
- 1-17;
- 37-43% by weight sugar;
- 6-12% by weight buffer salts;
- 7-13% by weight Ludipress (lactose, povidone, and crospovidone);
- and
- 0.5-1.5% by weight magnesium stearate,
- and a pharmaceutical acceptable carrier or vehicle.
5 more elements
A formulation in the form of a tablet comprising:
- 40% by weight alkaline phosphatase (AP)-based agent, wherein the AP-based agent comprises an amino acid sequence at least 95% identical to the amino acid sequences set forth in SEQ ID NOs:
- 1-17;
- 40% by weight sugar;
- 9% by weight buffer salts;
- 10% by weight Ludipress (lactose, povidone, and crospovidone);
- and
- 1% by weight magnesium stearate,
- and a pharmaceutical acceptable carrier or vehicle.
5 more elements
Dependencies are inferred from the claim text.